You are here

Article Text

Article menu

other Versions

Download PDFPDF
PostScript
Letter
Authors' response
  1. Amardeep Singh,
  2. Torben Lykke Sørensen
  1. Department of Ophthalmology, Copenhagen University Hospital, Roskilde, Denmark
  1. Correspondence to Dr Amardeep Singh, Department of Ophthalmology, Copenhagen University Hospital, Roskilde, Køgevej 7-13, DK-4000 Roskilde, Denmark; asingh{at}dadlnet.dk

https://doi.org/10.1136/bjo.2011.205203

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We thank Dr Meyer and colleagues for their valuable and relevant input on the incidence and regression of Charles Bonnet syndrome (CBS) in neovascular age-related macular degeneration (AMD).

    We introduced intravitreal ranibizumab treatment for neovascular AMD in our clinic in 2007; our database for these patients therefore dates back to this year. Based on these data, the median duration of therapy in our CBS patients was 450 days (range 129–877). We do not have specific data regarding the presence of macular degeneration in these patients prior to therapy commencement and are therefore unable …

    View Full Text

    Footnotes

    • Competing interests None.

    • Provenance and peer review Commissioned; not externally peer reviewed.

    Linked Articles